|Bid||13.17 x 800|
|Ask||13.18 x 1200|
|Day's Range||13.09 - 13.55|
|52 Week Range||8.37 - 19.34|
|Beta (5Y Monthly)||1.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.08|
Subscribe to Yahoo Finance Plus to view Fair Value for ISEE
PARSIPPANY, N.J., August 10, 2022--Pravin U. Dugel, M.D., President, will participate in a panel discussion at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference.
Biopharmaceutical companies have been struggling since 2021 and that narrative isn’t immediately changing. However, not every firm deserves this fate. In fact, investors can find great opportunities with “cheap” biotech stocks to buy now. There are many reasons for investor pessimism that could soon ease. For instance, drug innovation has stagnated in 2022. Companies also haven’t been able to announce as many positive clinical readouts to build confidence. These both could change in a jiffy if a
PARSIPPANY, N.J., August 03, 2022--Iveric Bio announced the Company will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022.